ANN MADSEN: Open Payments
NPI 1245779974 · AUBURN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$685 in 33 payments from 7 companies in 2025. Trend: 2023 $251 · 2024 $554 · 2025 $685
Food & beverage: $685
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $277 |
| Vanda Pharmaceuticals Inc. | 5 | $154 |
| ABBVIE INC. | 9 | $138 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
Products named: CAPLYTA, FANAPT, VRAYLAR, REXULTI, Qelbree, Auvelity, VIIBRYD, INGREZZA.
Industry payments across AL — which companies pay providers there.
